BP
ALXN

Ballentine Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Ballentine Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,946
Closed -$272K – 443
2017
Q3 		$272K Sell
1,946
-9
-0.5% -$1.22K 0.02% 290
2017
Q2 		$253K Buy
+1,955
New +$228K 0.02% 303
2016
Q2 		– Sell
-1,638
Closed -$228K – 243
2016
Q1 		$228K Buy
+1,638
New +$241K 0.02% 180

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ballentine Partners's ALXN Position: Q4 2017 in Review

Ballentine Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 1,946 shares — an estimated $272K sold.

Ballentine Partners first reported a position in ALXN in Q1 2016 and held it in 3 quarters. The position peaked at $272K in Q3 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Ballentine Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Ballentine Partners sold 1,946 Alexion Pharmaceuticals shares in Q4 2017, an estimated $272K.
  • Ballentine Partners first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Ballentine Partners's Alexion Pharmaceuticals position peaked at $272K in Q3 2017.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Ballentine Partners's 13F filing for Q4 2017, filed 2 Feb 2018.